Technology
Health
Biotechnology

XOMA

$16.42
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.24 (1.48%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell XOMA and other stocks, options, ETFs, and crypto commission-free!

About

XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. Read More The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Employees
11
Headquarters
Emeryville, California
Founded
1981
Market Cap
141.16M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
86.95K
High Today
$17.03
Low Today
$15.88
Open Price
$16.14
Volume
26.77K
52 Week High
$25.99
52 Week Low
$11.02

Collections

Technology
Health
Biotechnology
Therapy
US
North America

News

Yahoo FinanceMay 6

XOMA Reports First Quarter 2019 Financial Results and Operating Highlights

Acquired rights to potential milestone and royalty payments associated with five hematology assets Received $5.5 million milestone payment Added Barbara Kosacz to XOMA’s Board of Directors Current cash balance sufficient to fund operations for multiple years EMERYVILLE, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (XOMA) announced its first quarter 2019 financial results and business highlights. “We continued to execute on our royalty-aggregator business model in 2019. In early April, we a...

41

Earnings

-$1.54
-$0.96
-$0.37
$0.21
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.12 per share
Actual
$0.21 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.